| Market Capitalization (Millions $) |
- |
| Shares
Outstanding (Millions) |
223 |
| Employees |
3,837 |
| Revenues (TTM) (Millions $) |
6,262 |
| Net Income (TTM) (Millions $) |
535 |
| Cash Flow (TTM) (Millions $) |
1,151 |
| Capital Exp. (TTM) (Millions $) |
225 |
Business Description
Overview of Alexion Pharmaceuticals Inc.
Alexion Pharmaceuticals Inc. is a biopharmaceutical company that specializes in the development and commercialization of life-transforming therapeutic products aimed at patients suffering from severe and ultra-rare disorders. Founded in 1992, Alexion has a strong commitment to addressing unmet medical needs through innovation and cutting-edge science.
Core Products and Focus
The flagship product of Alexion Pharmaceuticals is Soliris® (eculizumab), which has gained recognition as the first and only therapy approved for treating two severe and ultra-rare disorders arising from chronic uncontrolled activation of the complement system of the immune system:
1. Paroxysmal Nocturnal Hemoglobinuria (PNH):
- A genetic blood disorder characterized by the destruction of red blood cells (hemolysis) due to uncontrolled complement activation. Symptoms include severe anemia, fatigue, kidney damage, and thrombosis.
- Approved for PNH treatment by the U.S. FDA and the European Commission in 2007, with approvals in additional territories following thereafter.
2. Atypical Hemolytic Uremic Syndrome (aHUS):
- A rare disease causing blood clots in small blood vessels, leading to serious complications like kidney damage and systemic thrombotic microangiopathy.
- Soliris was approved for aHUS treatment by the FDA in September 2011 and by the European Commission later that year.
Mechanism of Action
Soliris functions as a C5 complement inhibitor, specifically blocking the terminal complement pathway to reduce inflammation associated with various chronic disorders. This immunomodulatory action is crucial for the management of ailments related to hematology, nephrology, transplant rejection, and neurology.
Other Development Programs
In addition to PNH and aHUS, Alexion is advancing its portfolio of other therapeutic candidates targeting rare diseases that share the mechanism of uncontrolled complement activation:
- Cold Agglutinin Disease (CAD):
A severe autoimmune disorder characterized by hemolysis triggered by antibodies against red blood cells.
- Neuromyelitis Optica (NMO) and Myasthenia Gravis (MG):
Autoimmune diseases with significant neurological implications that are being investigated through ongoing clinical trials featuring eculizumab.
- Shiga-Toxin Producing E. Coli Hemolytic Uremic Syndrome (STEC-HUS):
A complement-mediated disorder arising from E. coli infection, currently under clinical investigation for treatment with eculizumab.
- Hypophosphatasia (HPP):
A severe metabolic disorder treated with asfotase alfa, aimed at reducing enzyme deficiencies that lead to bone and organ damage.
- Molybdenum Cofactor Deficiency (MoCD):
A rare metabolic disorder for which Alexion is working on cPMP replacement therapy.
- Complement Inhibitor Programs:
Including investigational compounds designed to inhibit different pathways in the complement cascade, potentially offering novel treatment avenues.
Competitive Landscape
While Soliris is currently the only approved treatment for both PNH and aHUS, Alexion faces competition from various biopharmaceutical firms working on complement inhibitors and therapies for related disorders. The competition is characterized by:
- Research and Development Investments:
Other pharmaceutical and biotechnology companies have considerable resources devoted to drug development and may be working on treatments targeting similar diseases.
- Potential Market Entry of New Therapies:
New entrants into the complement therapeutic landscape could challenge Alexion’s market position, leveraging distinctions in mechanism of action and efficacy to attract patients and healthcare providers.
Conclusion
Alexion Pharmaceuticals continues to solidify its role as a leader in the treatment of rare and severe diseases through a robust pipeline centered around complement inhibition. With ongoing research and development, the company is poised to explore new frontiers in biopharmaceutical innovation, aiming to extend its impact on patient care globally.
Company Address: 121 Seaport Boulevard Boston 2210 MA
Company Phone Number: 230-2596 Stock Exchange / Ticker: NASDAQ ALXN
|
%
